

Ref: FOI/GS/ID 7250

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

22 February 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to non-small cell lung cancer (NSCLC).

You asked:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- a. Afatinib*
- b. Alectinib*
- c. Atezolizumab monotherapy*
- d. Atezolizumab with chemotherapy*
- e. Bevacizumab*
- f. Brigatinib*
- g. Ceritinib*
- h. Crizotinib*
- i. Dacomitinib*
- j. Dabrafenib with Trametinib*
- k. Docetaxel monotherapy or combination with Carboplatin/Cisplatin*
- l. Durvalumab*
- m. Erlotinib*
- n. Gefitinib*
- o. Gemcitabine*
- p. Lorlatinib*
- q. Nintedanib with Docetaxel*
- r. Nivolumab*
- s. Osimertinib*
- t. Paclitaxel*
- u. Pembrolizumab monotherapy*
- v. Pembrolizumab with chemotherapy*
- w. Pemetrexed with Carboplatin/Cisplatin*

- x. *Tepotinib*
- y. *Vinorelbine with Carboplatin/Cisplatin*
- z. *Any other active systemic anti-cancer therapy (SACT)*
- aa. *Palliative care only*

Q2. *In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:*

- a. *Atezolizumab monotherapy*
- b. *Atezolizumab with chemotherapy*
- c. *Durvalumab*
- d. *Gemcitabine*
- e. *Nivolumab*
- f. *Osimertinib*
- g. *Paclitaxel*
- h. *Pembrolizumab (Keytruda) Mono*
- i. *Pembrolizumab (Keytruda) with Chemotherapy*
- j. *Other active systemic anti-cancer therapy (SACT)*
- k. *Palliative care only*

Trust response:

Q1:

- a. 2
- b. 5
- c. 2
- d. 0
- e. 0
- f. 1
- g. 0
- h. 2
- i. 0
- j. 0
- k. 2
- l. 5
- m. 0
- n. 1
- o. 0
- p. 1
- q. 0
- r. 0
- s. 15
- t. 0
- u. 16
- v. 29
- w. 3
- x. 0
- y. 9
- z. 11
- aa. 0

Q2:

a. 2
b. 0
c. 1
d. 0
e. 0
f. 1
g. 0
h. 4
i. 3
j. 4
k. 2